GlobeNewswire: Profound Medical Inc. Contains the last 10 of 222 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T12:22:49ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/07/2842730/0/en/Profound-Medical-Announces-Fourth-Quarter-and-Full-Year-2023-Financial-Results.html?f=22&fvtc=4&fvtv=23742Profound Medical Announces Fourth Quarter and Full Year 2023 Financial Results2024-03-07T21:05:00Z<![CDATA[TORONTO, March 07, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today reported financial results for the fourth quarter and full year ended December 31, 2023. Unless specified otherwise, all amounts in this press release are expressed in U.S. dollars and are presented in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board.]]>https://www.globenewswire.com/news-release/2024/03/04/2840001/0/en/Profound-Medical-to-Participate-in-Barclays-26th-Annual-Global-Healthcare-Conference.html?f=22&fvtc=4&fvtv=23742Profound Medical to Participate in Barclays 26th Annual Global Healthcare Conference2024-03-04T21:30:00Z<![CDATA[TORONTO, March 04, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13, 2024 at 11:15 a.m. Eastern Time at the Loews Miami Beach Hotel.]]>https://www.globenewswire.com/news-release/2024/02/27/2835914/0/en/Profound-Medical-in-Collaboration-with-Siemens-Healthineers-to-Further-Expand-Physician-and-Patient-Access-to-the-TULSA-Procedure.html?f=22&fvtc=4&fvtv=23742Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure2024-02-27T12:45:00Z<![CDATA[TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has entered into a non-exclusive collaboration with Siemens Healthineers, a global leader in medical technology. The collaboration is aimed at laying the groundwork for Profound to begin marketing a complete therapeutics solution, combining its TULSA-PRO® system with the MAGNETOM Free.Max magnetic resonance (“MR”) scanner from Siemens Healthineers, via Profound’s own sales force. Profound will also continue to market TULSA-PRO® as a stand-alone offering, providing its customers with the flexibility to use the technology with the MR hardware of their choice.]]>https://www.globenewswire.com/news-release/2024/02/15/2830413/0/en/Profound-Medical-to-Release-Fourth-Quarter-and-Full-Year-2023-Financial-Results-on-March-7-Conference-Call-to-Follow.html?f=22&fvtc=4&fvtv=23742Profound Medical to Release Fourth Quarter and Full Year 2023 Financial Results on March 7 – Conference Call to Follow2024-02-15T21:30:00Z<![CDATA[TORONTO, Feb. 15, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its fourth quarter and full year 2023 financial results after market close on Thursday, March 7, 2024.]]>https://www.globenewswire.com/news-release/2024/01/16/2810346/0/en/Profound-Medical-Announces-Non-Brokered-Private-Placement.html?f=22&fvtc=4&fvtv=23742Profound Medical Announces Non-Brokered Private Placement2024-01-16T21:30:00Z<![CDATA[TORONTO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) ("Profound" or the "Company") is pleased to announce that the Company has entered into subscription agreements, dated as of January 16, 2024, with certain existing Canadian institutional investors, in connection with a non-brokered private placement (the "Private Placement") for aggregate gross proceeds of approximately US$2,937,502.]]>https://www.globenewswire.com/news-release/2024/01/03/2803635/0/en/Profound-Medical-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Revenues.html?f=22&fvtc=4&fvtv=23742Profound Medical Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Revenues2024-01-03T21:15:00Z<![CDATA[TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced preliminary unaudited revenues for the fourth quarter and full year 2023, and provided an update on the progress it is making with the commercialization of TULSA-PRO® in the United States. Profound is providing this information due to the significant lag time between planned investment community meetings to be held in connection with, among other investor events, the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, and its expected reporting of final 2023 results in March 2024.]]>https://www.globenewswire.com/news-release/2023/12/28/2801560/0/en/Profound-Medical-Announces-Pricing-of-US-20-Million-Public-Offering-of-Common-Shares.html?f=22&fvtc=4&fvtv=23742Profound Medical Announces Pricing of US$20 Million Public Offering of Common Shares2023-12-28T03:40:00Z<![CDATA[TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) today announced the pricing of its previously announced underwritten public offering (the “Offering”) of 2,666,667 common shares (the “Common Shares”) at a price to the public of US$7.50 per Common Share, led by healthcare focused institutional investors. Gross proceeds to the Company from the Offering are expected to be approximately US$20,000,000, prior to deducting underwriting discounts and commissions and other expenses related to the Offering, assuming no exercise of the underwriter's over-allotment option.]]>https://www.globenewswire.com/news-release/2023/12/27/2801528/0/en/Profound-Medical-Announces-Proposed-Public-Offering-of-Common-Shares.html?f=22&fvtc=4&fvtv=23742Profound Medical Announces Proposed Public Offering of Common Shares2023-12-27T21:15:00Z<![CDATA[TORONTO, Dec. 27, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (TSX:PRN; NASDAQ:PROF) (“Profound” or the “Company”) is pleased to announce the commencement of an underwritten public offering in the United States of common shares (the “Common Shares”) in the capital of the Company (the “Offering”). The Company intends to file a preliminary prospectus supplement (the “Preliminary Supplement”) to its short form base shelf prospectus dated March 23, 2022 (the “Base Shelf Prospectus”) in the United States and Canada relating to the proposed Offering. The Company intends that the Offering will be priced in the context of the market, with such price and the total size of the Offering to be determined at the time of entering into an underwriting agreement with respect thereto. The Company expects to grant the underwriter for the Offering an over-allotment option to purchase up to an additional 15% of the Common Shares to be sold pursuant to the Offering on the same terms and conditions, and that the over-allotment option will be exercisable for a period of 30 days after closing. All of the securities in the offering will be sold by the Company.]]>https://www.globenewswire.com/news-release/2023/11/08/2776136/0/en/Profound-Medical-to-Participate-in-the-Stifel-2023-Healthcare-Conference.html?f=22&fvtc=4&fvtv=23742Profound Medical to Participate in the Stifel 2023 Healthcare Conference2023-11-08T12:45:00Z<![CDATA[TORONTO, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that management will present an update on the Company’s business at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. Eastern Time in NYC.]]>https://www.globenewswire.com/news-release/2023/11/03/2773149/0/en/Profound-Medical-Announces-CMS-Extension-of-Temporary-Code-for-TULSA-to-ASC-Setting.html?f=22&fvtc=4&fvtv=23742Profound Medical Announces CMS Extension of Temporary ‘Code’ for TULSA to ASC Setting2023-11-03T12:00:00Z<![CDATA[TORONTO, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, announced today that, pursuant to the 2024 Final Rule published yesterday by the U.S. Centers for Medicare and Medicaid Services (“CMS”), use of HCPCS C code, C9734, previously established for the Hospital Outpatient Prospective Payment System (OPPS), has been extended for use in the Ambulatory Surgical Center (“ASC”) setting, and that MRI-Monitored Transurethral Ultrasound Ablation (“TULSA”) of prostate tissue, performed using Profound’s TULSA-PRO® system, has been assigned device-intensive status. The ASC extension will go into effect on January 1, 2024.]]>